Corium International Inc (NASDAQ:CORI) major shareholder Perceptive Advisors Llc purchased 50,350 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was bought at an average cost of $11.83 per share, with a total value of $595,640.50. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of Corium International Inc (NASDAQ CORI) opened at $13.63 on Friday. Corium International Inc has a one year low of $2.67 and a one year high of $13.85. The company has a debt-to-equity ratio of 2.41, a current ratio of 2.70 and a quick ratio of 2.60.
Corium International (NASDAQ:CORI) last released its earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. Corium International had a negative return on equity of 482.64% and a negative net margin of 149.99%. sell-side analysts anticipate that Corium International Inc will post -1.47 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. grew its stake in Corium International by 47.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 49,509 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 15,909 shares during the period. New York State Common Retirement Fund acquired a new stake in Corium International during the second quarter worth approximately $158,000. Bank of New York Mellon Corp grew its stake in Corium International by 33.7% during the third quarter. Bank of New York Mellon Corp now owns 88,445 shares of the biopharmaceutical company’s stock worth $980,000 after purchasing an additional 22,285 shares during the period. California State Teachers Retirement System acquired a new stake in Corium International during the second quarter worth approximately $263,000. Finally, Teachers Advisors LLC acquired a new stake in Corium International during the second quarter worth approximately $272,000. 89.08% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a research note on Tuesday, November 28th. Needham & Company LLC increased their price target on Corium International from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, November 20th. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 price target on shares of Corium International in a research note on Friday, December 22nd. HC Wainwright assumed coverage on Corium International in a research note on Tuesday, September 26th. They issued a “buy” rating and a $15.00 price target for the company. Finally, ValuEngine raised Corium International from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. Corium International presently has a consensus rating of “Buy” and an average price target of $12.86.
COPYRIGHT VIOLATION WARNING: This article was first reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.truebluetribune.com/2018/01/21/insider-buying-corium-international-inc-cori-major-shareholder-purchases-595640-50-in-stock.html.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.